Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector
Details : Midazolam 10 mg autoinjector is indicated for the treatment of status epilepticus, or prolonged seizures, in adults. According to U.S. JPEO-CBRND, the autoinjector improves upon and will replace the currently fielded convulsant antidote for nerve agent d...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 30, 2022
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Midazolam in Healthy Adults
Details : Midazolam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Status Epilepticus.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 22, 2020
Reset All
